INT115464

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.72
First Reported 2002
Last Reported 2010
Negated 2
Speculated 5
Reported most in Body
Documents 41
Total Number 48
Disease Relevance 30.21
Pain Relevance 2.79

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

peptidase activity (Plau) extracellular space (Plau) extracellular region (Plau)
kinase activity (Plau)
Anatomy Link Frequency
endothelial cells 3
extracellular matrix 3
plasma 2
hepatocytes 2
liver 2
Plau (Mus musculus)
Pain Link Frequency Relevance Heat
metalloproteinase 344 100.00 Very High Very High Very High
COX-2 inhibitor 22 98.12 Very High Very High Very High
Inflammation 401 97.40 Very High Very High Very High
Inflammatory mediators 21 96.96 Very High Very High Very High
cytokine 110 87.56 High High
Inflammatory response 16 71.40 Quite High
Potency 25 69.04 Quite High
chemokine 36 66.24 Quite High
rheumatoid arthritis 38 50.80 Quite High
Angina 6 50.00 Quite Low
Disease Link Frequency Relevance Heat
Severe Combined Immunodeficiency 86 100.00 Very High Very High Very High
Cancer 1911 99.98 Very High Very High Very High
Breast Cancer 471 99.84 Very High Very High Very High
Ovarian Cancer 53 98.80 Very High Very High Very High
Metastasis 490 98.00 Very High Very High Very High
INFLAMMATION 441 97.40 Very High Very High Very High
Aggression 6 97.36 Very High Very High Very High
Death 24 96.72 Very High Very High Very High
Adhesions 61 95.28 Very High Very High Very High
Adenoma 20 92.84 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
We carried out experiments to investigate whether the COX-2 inhibitor celecoxib at a dose of either 200 mg bid or 400 mg bid could significantly affect endogenous uPA, PAI-1 or PGE2 production in women at increased risk for breast cancer.
Gene_expression (production) of uPA associated with breast cancer and cox-2 inhibitor
1) Confidence 0.72 Published 2008 Journal BMC Cancer Section Body Doc Link PMC2580770 Disease Relevance 0.17 Pain Relevance 0.05
uPA expression trended downward among women receiving the lower celecoxib dose and upward among those receiving the higher dose, suggesting a dose-dependent effect of the medication.
Gene_expression (expression) of uPA
2) Confidence 0.72 Published 2008 Journal BMC Cancer Section Body Doc Link PMC2580770 Disease Relevance 0.26 Pain Relevance 0.03
Tumors expressing proteolytically inactive uPA mutants grew faster than tumors overexpressing proteolytically active uPA, suggesting that the inhibitory actions were mediated by uPA's protease activity [8].
Gene_expression (overexpressing) of uPA associated with cancer
3) Confidence 0.72 Published 2008 Journal BMC Cancer Section Body Doc Link PMC2580770 Disease Relevance 1.50 Pain Relevance 0
In a mouse mammary cancer model, induced uPA expression delayed tumor progression and had antiangiogenic and antiproliferative effects.
Gene_expression (expression) of uPA associated with cancer
4) Confidence 0.72 Published 2008 Journal BMC Cancer Section Body Doc Link PMC2580770 Disease Relevance 1.58 Pain Relevance 0
Tumors expressing proteolytically inactive uPA mutants grew faster than tumors overexpressing proteolytically active uPA, suggesting that the inhibitory actions were mediated by uPA's protease activity [8].
Neg (inactive) Gene_expression (expressing) of uPA associated with cancer
5) Confidence 0.63 Published 2008 Journal BMC Cancer Section Body Doc Link PMC2580770 Disease Relevance 1.54 Pain Relevance 0
We first evaluated the change in uPA, PAI-1 and PGE2 concentration in the NAF of each participant after low and high dose celecoxib administration (Table 2).
Gene_expression (concentration) of uPA
6) Confidence 0.63 Published 2008 Journal BMC Cancer Section Body Doc Link PMC2580770 Disease Relevance 0 Pain Relevance 0
uPA levels in postmenopausal women increase, while PAI-1 and PGE2 decrease, after treatment with high dose celecoxib
Gene_expression (levels) of uPA
7) Confidence 0.63 Published 2008 Journal BMC Cancer Section Body Doc Link PMC2580770 Disease Relevance 0 Pain Relevance 0
An increased propensity for extracellular matrix (ECM) remodeling is suggested by elevated expression of matrix metalloproteinases (Mmp3, Mmp9 and Mmp13), urokinase-type plasminogen activator (Plau) and secreted protease inhibitors (Serpina3g, Serpin2 and Lcn2).
Gene_expression (expression) of urokinase-type plasminogen activator in extracellular matrix associated with metalloproteinase
8) Confidence 0.56 Published 2008 Journal BMC Cancer Section Body Doc Link PMC2529338 Disease Relevance 0.43 Pain Relevance 0.11
An increased propensity for extracellular matrix (ECM) remodeling is suggested by elevated expression of matrix metalloproteinases (Mmp3, Mmp9 and Mmp13), urokinase-type plasminogen activator (Plau) and secreted protease inhibitors (Serpina3g, Serpin2 and Lcn2).
Gene_expression (expression) of Plau in extracellular matrix associated with metalloproteinase
9) Confidence 0.56 Published 2008 Journal BMC Cancer Section Body Doc Link PMC2529338 Disease Relevance 0.43 Pain Relevance 0.11
Our previous experience using celecoxib to inhibit eicosanoid production, the fact that celecoxib affects uPA production and the conflicting findings regarding the role of uPA and PAI-1 in tumor progression caused us to investigate the expression of uPA and PAI-1 in the breast and uPA systemically before and after treatment with low (200 mg bid) and high (400 mg bid) dose celecoxib.


Gene_expression (production) of uPA associated with cancer
10) Confidence 0.56 Published 2008 Journal BMC Cancer Section Body Doc Link PMC2580770 Disease Relevance 0.75 Pain Relevance 0.04
While increased urokinase-type plasminogen activator (uPA) expression in breast cancer tissue is directly associated with poor prognosis, recent evidence suggests that uPA overexpression may suppress tumor growth and prolong survival.
Gene_expression (overexpression) of uPA associated with cancer and breast cancer
11) Confidence 0.56 Published 2008 Journal BMC Cancer Section Abstract Doc Link PMC2580770 Disease Relevance 0.43 Pain Relevance 0
It therefore appears that the association of uPA and PAI-1 expression with breast cancer is complex.
Gene_expression (expression) of uPA associated with breast cancer
12) Confidence 0.56 Published 2008 Journal BMC Cancer Section Body Doc Link PMC2580770 Disease Relevance 1.36 Pain Relevance 0.03
Our previous experience using celecoxib to inhibit eicosanoid production, the fact that celecoxib affects uPA production and the conflicting findings regarding the role of uPA and PAI-1 in tumor progression caused us to investigate the expression of uPA and PAI-1 in the breast and uPA systemically before and after treatment with low (200 mg bid) and high (400 mg bid) dose celecoxib.


Spec (investigate) Gene_expression (expression) of uPA associated with cancer
13) Confidence 0.56 Published 2008 Journal BMC Cancer Section Body Doc Link PMC2580770 Disease Relevance 0.76 Pain Relevance 0.03
We sought to determine if uPA, PA inhibitor (PAI)-1 and prostaglandin (PG)E2 expression in nipple aspirate fluid (NAF) and uPA and PGE2 expression in plasma were altered by celecoxib dose and concentration in women at increased breast cancer risk.


Gene_expression (expression) of uPA in plasma associated with breast cancer
14) Confidence 0.56 Published 2008 Journal BMC Cancer Section Abstract Doc Link PMC2580770 Disease Relevance 0.44 Pain Relevance 0
While increased urokinase-type plasminogen activator (uPA) expression in breast cancer tissue is directly associated with poor prognosis, recent evidence suggests that uPA overexpression may suppress tumor growth and prolong survival.
Gene_expression (expression) of uPA associated with cancer and breast cancer
15) Confidence 0.56 Published 2008 Journal BMC Cancer Section Abstract Doc Link PMC2580770 Disease Relevance 0.41 Pain Relevance 0
While increased urokinase-type plasminogen activator (uPA) expression in breast cancer tissue is directly associated with poor prognosis, recent evidence suggests that uPA overexpression may suppress tumor growth and prolong survival.
Gene_expression (expression) of urokinase-type plasminogen activator associated with cancer and breast cancer
16) Confidence 0.56 Published 2008 Journal BMC Cancer Section Abstract Doc Link PMC2580770 Disease Relevance 0.41 Pain Relevance 0
Celecoxib has been reported to inhibit uPA production in MDA-MB-231 breast cancer cells [17].
Gene_expression (production) of uPA in MDA-MB-231 associated with breast cancer
17) Confidence 0.56 Published 2008 Journal BMC Cancer Section Body Doc Link PMC2580770 Disease Relevance 1.08 Pain Relevance 0.04
To standardize uPA and PAI-1 expression in NAF, total protein was measured for each sample with a BCA protein assay kit (Pierce Chemicals, Rockford, IL), and results reported as pg of uPA or PAI-1 per mg total NAF protein.


Gene_expression (expression) of uPA
18) Confidence 0.56 Published 2008 Journal BMC Cancer Section Body Doc Link PMC2580770 Disease Relevance 0 Pain Relevance 0
We sought to determine if uPA, PA inhibitor (PAI)-1 and prostaglandin (PG)E2 expression in nipple aspirate fluid (NAF) and uPA and PGE2 expression in plasma were altered by celecoxib dose and concentration in women at increased breast cancer risk.


Gene_expression (expression) of uPA in plasma associated with breast cancer
19) Confidence 0.56 Published 2008 Journal BMC Cancer Section Abstract Doc Link PMC2580770 Disease Relevance 0.45 Pain Relevance 0
While uPA has both positive and negative actions in cancer, PAI-1 promotes breast cancer invasion and metastasis.
Neg (negative) Gene_expression (has) of uPA associated with cancer, breast cancer and metastasis
20) Confidence 0.55 Published 2008 Journal BMC Cancer Section Body Doc Link PMC2580770 Disease Relevance 1.58 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox